Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Published:2022-10 Issue:10 Volume:17 Page:1192-1204
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lu Shun^ORCID,Zhang Yiping,Zhang Guojun,Zhou Jianying,Cang Shundong,Cheng Ying,Wu Gang,Cao Peiguo,Lv Dongqing,Jian Hong,Chen Chengshui,Jin Xiangming,Tian Panwen,Wang Kai,Jiang Guanming,Chen Gongyan,Chen Qun,Zhao Hui,Ding Cuimin,Guo Renhua,Sun Guoping,Wang Bin,Jiang Liyan,Liu Zhe,Fang Jian,Yang Junquan,Zhuang Wu,Liu Yunpeng,Zhang Jian,Pan Yueyin,Chen Jun,Yu Qitao,Zhao Min,Cui Jiuwei,Li Dianming,Yi Tienan,Yu Zhuang,Yang Yan,Zhang Yan,Zhi Xiuyi,Huang Yunchao,Wu Rong,Chen Liangan,Zang Aimin,Cao Lejie,Li Qingshan,Li Xiaoling,Song Yong,Wang Donglin,Zhang Shucai,Ding Lieming,Zhang Ling,Yuan Xiaobin,Yao Lin,Shen Zhilin

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Lung cancer mortality in China: spatial and temporal trends among subpopulations;Wang;Chest,2019

3. Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with second-line therapies for Medicare patients with advanced non-small-cell lung cancer;Arunachalam;Clin Lung Cancer,2018

4. Specific organ metastases and survival in metastatic non-small-cell lung cancer;Tamura;Mol Clin Oncol,2015

5. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis;Yang;Int J Cancer,2017

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial;Lung Cancer;2024-09

2. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

3. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.;Lung Cancer: Targets and Therapy;2024-06

4. The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review);Oncology Reports;2023-12-05

5. New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations;Cancers;2023-10-20